FDA approves combination therapy Juvisync

published:  12/3/2011 author: مدیر سایت visitors:  597 comments:  0
FDA approves combination therapy Juvisync

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin. About 20 million people in the United States have type 2 diabetes, and they often have high cholesterol levels as well. These co... read more

FDA Approves Combivent Respimat Inhalation Spray

published:  12/3/2011 author: مدیر سایت visitors:  421 comments:  0
FDA Approves Combivent Respimat Inhalation Spray

Combivent Respimat is a suitable alternative for patients who are currently using Combivent (ipratropium bromide and albuterol sulfate) Inhalation Aerosol. Combivent Inhalation Aerosol is being phased out because it contains chlorofluorocarbons (CFCs). CFCs are chemical compounds that decrease the ozone layer. As a result, Combivent Inhalation Aerosol will not be available after December 31, 2013.... read more

FDA approves Interrmezzo for insomnia

published:  12/3/2011 author: مدیر سایت visitors:  385 comments:  0
FDA approves Interrmezzo for insomnia

This is the first time the FDA has approved a drug for this condition. Intermezzo should only be used when a person has at least four hours of bedtime remaining. It should not be taken if alcohol has been consumed or with any other sleep aid. Insomnia is a common condition in which a person has trouble falling or staying asleep. It can range from mild to severe, depending on how often it occurs a... read more

FDA approves first generic version of cholesterol-lowering drug Lipitor

published:  12/3/2011 author: مدیر سایت visitors:  366 comments:  0
FDA approves first generic version of cholesterol-lowering drug Lipitor

The U.S. Food and Drug Administration today approved the first generic version of the cholesterol-lowering drug Lipitor (atorvastatin calcium tablets). Ranbaxy Laboratories Ltd. has gained approval to make generic atorvastatin calcium tablets in 10 milligram, 20 mg, 40 mg, and 80 mg strengths. The drug will be manufactured by Ohm Laboratories in New Brunswick, N.J. People who have high blood... read more